MIMEDX to Participate at the Jefferies Virtual Healthcare Conference
MIMEDX Group, an industry leader in regenerative medicine using amniotic tissue, announced that key executives will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.
Date: June 4, 2021
Time: 2:00 PM ET
Webcast Link: Join Here
MIMEDX specializes in developing placental tissue allografts for healthcare sectors, processing tissues through proprietary methods and maintaining high production standards.
- None.
- None.
MARIETTA, Ga., May 27, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 2:00 PM Eastern Time.
Date: Friday, June 4, 2021
Time: 2:00 PM ET
Webcast: https://wsw.com/webcast/jeff174/mdxg/1854576
A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com or through the conference site by using the link above. A replay will be available on the Company’s website following the event.
About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a core business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contacts:
Investors
Jack Howarth
404-360-5681
investorrelations@MIMEDX.com
FAQ
What is the date and time of MIMEDX's participation in the Jefferies Virtual Healthcare Conference?
Where can I watch the MIMEDX fireside chat?
Who from MIMEDX will be speaking at the Jefferies Virtual Healthcare Conference?
What does MIMEDX specialize in?
How does MIMEDX ensure the quality of its products?
What is the stock symbol for MIMEDX?
